Skip to main content
. 2025 Feb 19;85(3):343–360. doi: 10.1007/s40265-024-02138-w
The numbers of ‘the oldest old’ are set to rise over the coming years, and with this the burden of osteoporosis and osteoarthritis will expand.
At present, evidence for treatments for osteoporosis and osteoarthritis is lacking in this age group (with post hoc analysis playing a major role in demonstrating fracture risk reduction efficacy in anti-osteoporosis medications) and should be the subject of a future research agenda, including clinical trials.